NCT02530463 2026-03-05Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeM.D. Anderson Cancer CenterPhase 2 Active not recruiting99 enrolled
NCT02879695 2025-08-15Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 1 Active not recruiting28 enrolled 16 charts